Menu
Recruiting NCT07095426

Impact of Supplemental Fiber on Gut and Vascular Health Related in Obesity Phenotypes

No phase Interventional Metabolic Syndrome Healthy Participants Metabolically Healthy Obesity Metabolically Abnormal Obesity

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: inulin.
Who it may be relevant to
Registry conditions: Metabolic Syndrome, Healthy Participants, Metabolically Healthy Obesity, Metabolically Abnormal Obesity. Basic parameters: 18 years — 55 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Interplay Between Metabolic Risk Factors, Body Mass Index, and the Gut/Vascular Response to Supplemental Fiber

Overview

Based on prior research, the investigators are interested in whether an intervention targeting gut health (supplemental fiber for 9 weeks total) will improve vascular health in individuals with obesity. Additionally, the investigators are interested in if this response differs based on whether individuals with obesity have very few heart disease risk factors or several heart disease risk factors.

Detailed description

The investigators will recruit individuals with obesity (body mass index ≥30 kg/m2) from Ball State University Campus and the surrounding community. Participants will be grouped as "metabolically healthy" (0-1 metabolic syndrome risk factors) or "metabolically unhealthy" (≥2 metabolic syndrome risk factors) Participants will be asked to consume inulin for 9 weeks total. Participants will consume 6g of inulin per day during week 1 as a run-in period. The following 8 weeks participants will consume 12g of inulin per day.

Participants will be asked to report for in-lab assessments/visits before the study begins (baseline), halfway through the intervention which starts following the 1-week run-in period (5 weeks), and at the conclusion of the intervention (9 weeks). At all of these assessments, participants will arrive in the morning (roughly 6-10 AM) having fasted for \~10 hours. We will then collect a blood sample, followed by several vascular measurements including flow-mediated dilation, pulse wave analysis, pulse wave velocity, and an electrocardiogram. Body weight and composition will also be assessed using a bioimpedance scale at each visit. Upon completion of each in-lab visit, participants will be asked to wear an ambulatory blood pressure monitoring device for 24 hours and will complete a 3-day food record. Dual-energy X-ray absorptiometry scans will be used to assess body composition at baseline and final study visits. Participants will provide a stool sample collected at home following baseline and final study visits as an optional procedure.

Interventions

  • Dietary supplement inulin
    6g inulin from chicory root per day for one week and 12g inulin per day for eight weeks dissolved into cool or room temperature liquid

Primary outcome measures

  • Serum Soluble Cluster of Differentiation 14 (sCD14) [Time frame: Through study completion, up to 1.5 years.]
  • Serum Lipopolysaccharide Binding Protein (LBP) [Time frame: Through study completion, up to 1.5 years.]
  • Serum C-Reactive Protein (CRP) [Time frame: Through study completion, up to 1.5 years.]
  • Heart Rate Variability (HRV) [Time frame: Through study completion, up to 1.5 years.]
  • Flow-Mediated Dilation (FMD) [Time frame: Through study completion, up to 1.5 years.]
  • Pulse Wave Velocity (PWV) [Time frame: Through study completion, up to 1.5 years.]
  • Aortic Aumentation [Time frame: Through study completion, up to 1.5 years.]
  • Augmentation Index (AIx) [Time frame: Through study completion, up to 1.5 years.]
Secondary outcome measures (5)
  • Blood Pressure [Time frame: Through study completion, up to 1.5 years.]
  • Glucose [Time frame: Through study completion, up to 1.5 years.]
  • High-Density Lipoprotein Cholesterol (HDL-C) [Time frame: Through study completion, up to 1.5 years.]
  • Triglycerides [Time frame: Through study completion, up to 1.5 years.]
  • Digestive Symptoms [Time frame: Through study completion, up to 1.5 years.]

Eligibility criteria

Inclusion criteria

  • Participants are 18-55 years old.
  • Participants BMI is ≥30 kg/m2 - this BMI requirement is due to our research aims.
  • Participants have either 0-1 or 2+ of the following risk factors outside of the normal reference ranges: blood pressure, blood sugar, triglycerides, and HDL-cholesterol.
  • Participants are not pregnant or expecting to become pregnant (females only). •Participants are not postmenopausal (females only).
  • Participants have not been diagnosed with an advanced cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes).
  • Participants have not been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease, diverticulosis/diverticulitis).
  • Participants do not regularly take anti-inflammatory drugs (more than 2x week) and are willing to suspend use of these medications for 3 days leading up to in-lab visits.
  • Participants do not take weight-loss medications (e.g., Ozempic, Wegovy).
  • Participants do not use tobacco products or any illicit drugs.
  • Participants have not used antibiotics or probiotics in the last month.
  • Participants do not have dietary restrictions prohibiting them from consuming the fiber supplement (e.g., food allergies/intolerance).
  • Participants do not have a pacemaker.
  • Participants are able to lie on their back (supine position) in the dark for at least 10 minutes (related to vascular measurements).

Exclusion criteria

  • Participants are not 18-55 years old.
  • Participants BMI is not ≥30 kg/m2 - this BMI requirement is due to our research aims.
  • Participants do not have either 0-1 or 2+ of the following risk factors outside of the normal reference ranges: blood pressure, blood sugar, triglycerides, and HDL-cholesterol.
  • Participants are pregnant or expecting to become pregnant (females only).
  • Participants are postmenopausal (females only).
  • Participants have been diagnosed with an advanced cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes).
  • Participants have been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease, diverticulosis/diverticulitis). •Participants regularly take anti-inflammatory drugs (more than 2x week) and are not willing to suspend use of these medications for 3 days leading up to in-lab visits.
  • Participants take weight-loss medications (e.g., Ozempic, Wegovy).
  • Participants use tobacco products or any illicit drugs.
  • Participants have used antibiotics or probiotics in the last month.
  • Participants have dietary restrictions prohibiting them from consuming the fiber supplement (e.g., food allergies/intolerance).
  • Participants have a pacemaker.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Other

Study locations

United States · 1 center
  • Health Professions Building — Muncie

Identifiers

NCT: NCT07095426 · IRB-FY2025-75

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗